8,040 men presenting with bone metastasis between 2010-2013 from the SEER database formed the study cohort. A Fine and Gray’s competing risks model was used to generate hazards ratios (HR) to identify predictors of PCSM. Kaplan-Meier analysis using log-rank test was used to assess PCSM stratified by extent of metastasis.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Men presenting with PCa-bone metastatic disease may have aggressive tumor biology and are at risk of PCSM in <3 years. Patients with aggressive prostate disease presenting with bone and concomitant visceral metastasis should be considered for early, aggressive systemic therapy and/or clinical trials.
Presented by: Zachary Klaassen, Toronto, Canada
Written by: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre, @GoldbergHanan, at the 18th Annual Meeting of the Society of Urologic Oncology, November 29-December 1, 2017 – Washington, DC